Oncotelic Therapeutics Inc Watch

from 8-K 7 pages Strictly Confidential David Chaplin, PH.D Chief Executive Officer Oxigene, Inc. 701 Gateway Blvd, Suite 210 South San Francisco, Ca 94080 Dear Dr. Chaplin

from 8-K 8 pages Strictly Confidential Peter J. Langecker, M.D., PH.D Chief Executive Officer Oxigene, Inc. 701 Gateway Blvd, Suite 210 South San Francisco, Ca 94080 Dear Dr. Langecker

from 8-K 8 pages Strictly Confidential Peter J. Langecker, M.D., PH.D Chief Executive Officer Oxigene, Inc. 701 Gateway Blvd, Suite 210 South San Francisco, Ca 94080 Dear Dr. Langecker

from 8-K 6 pages Strictly Confidential Peter J. Langecker, M.D., PH.D Chief Executive Officer Oxigene, Inc. 701 Gateway Blvd, Suite 210 South San Francisco, Ca 94080 Dear Dr. Langecker

from S-3 3 pages Amendment No. 1 to at Market Issuance Sales Agreement

from SC 13G/A ~1 page Joint Filing Agreement

from 8-K 44 pages 6,250,000 Units Oxigene, Inc. Placement Agent Agreement

from 8-K ~50 pages Ex-1.1 Underwriting Agreement Dated as of December 14, 2005

from 8-K 39 pages 3,336,117 Shares Oxigene, Inc. Common Stock Placement Agency Agreement

from SC 13G 1 page Exhibit 1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on Schedule 13g With Respect to the Common Stock of Oxigene, Inc. Is, and Any Amendment Thereto Signed by Each of the Undersigned Shall Be, Filed on Behalf of Each Undersigned Pursuant to and in Accordance With the Provisions of 13d-1(k) Under the Securities Exchange Act of 1934 and That All Subsequent Amendments to This Statement on Schedule 13g Shall Be Filed on Behalf of Each of the Undersigned Without the Necessity of Filing Additional Joint Filing Agreements. the Undersigned Acknowledge That Each Shall Be Responsible for the Timely Filing of Such Amendments, and for the Completeness and Accuracy of the Information Concerning It Contained Therein, but Shall Not Be Responsible for the Completeness and Accuracy of the Information Concerning the Other, Except to the Extent That It Knows or Has Reason to Believe That Such Information Is Inaccurate. Dated: January 21, 2004 Duquesne Capital Management, L.L.C. By: /S/ Gerald Kerner Name: Gerald Kerner Title: Managing Director Stanley F. Druckenmiller By: /S/ Gerald Kerner Name: Gerald Kerner Title: Attorney-In-Fact

from 8-K 44 pages Oxigene, Inc. 2,755,695 Shares of Common Stock Placement Agency Agreement

from S-3/A ~50 pages Form of Underwriting Agreement

from S-3/A ~50 pages Form of Underwriting Agreement